公司概述
Regeneron Pharmaceuticals, Inc. operates as a global biotechnology enterprise dedicated to discovering, inventing, developing, manufacturing, and commercializing medicines to treat a wide spectrum of diseases including those affecting the eyes, allergic and inflammatory conditions, cardiovascular and metabolic disorders, neurological issues, infectious diseases, and rare conditions. The company functions within the Healthcare sector and specifically within the Biotechnology industry, positioning itself as a developer of novel product candidates aimed at addressing complex medical needs worldwide. As of the latest data, Regeneron holds a substantial market capitalization of $81.99 billion and generates annual revenue of $14.34 billion while employing a workforce of 15,410 individuals. These valuation and revenue figures indicate that the company maintains a significant scale within the pharmaceutical landscape, reflecting its established presence and the substantial resources it commands in research and development as well as commercialization efforts.
财务健康
The company reported a trailing twelve-month revenue of $14.34 billion with a corresponding net income of $4.50 billion and an EBITDA of $4.25 billion. The gap between the $14.34 billion revenue and the $4.50 billion net income reveals a cost structure where approximately 68.4% of revenue is consumed by expenses including cost of goods sold, operating expenditures, and taxes, which is typical for a biotechnology firm with high R&D and manufacturing costs. Regeneron generated free cash flow of $3.26 billion, which provides the company with robust financial flexibility to fund its extensive pipeline of product candidates, return capital to shareholders, or pursue strategic acquisitions without needing external financing. The company maintains a gross margin of 44.6%, indicating the profitability after direct production costs; an operating margin of 23.1%, which reflects operational efficiency after covering all operating expenses; and a profit margin of 31.4%, demonstrating the final profitability relative to total sales after all costs including interest and taxes. In terms of liquidity and leverage, Regeneron holds $8.61 billion in cash against $2.97 billion in debt, resulting in a debt-to-equity ratio of 9.51, which suggests a balance sheet that is heavily weighted towards equity with minimal relative leverage. The current ratio stands at 4.13, a figure that indicates a very strong short-term liquidity position where current assets significantly exceed current liabilities, ensuring the company can easily meet its short-term obligations. Return on equity is reported at 14.9% and return on assets is 5.9%, metrics that reveal management's effectiveness in generating profits from the equity invested and utilizing the company's total asset base, respectively.
估值评估
Regeneron trades with a trailing twelve-month P/E ratio of 18.69 and a forward P/E of 14.74, implying that the market expects earnings to grow in the future as the forward multiple is notably lower than the trailing multiple. The price-to-book ratio is 2.55, indicating that the market values the company at a 155% premium over its net book value, which often reflects the intangible value of its intellectual property and pipeline potential. Alternative valuation metrics such as the price-to-sales ratio of 5.72 and an EV/EBITDA of 17.42 suggest that investors are pricing in significant future growth expectations and the high-quality earnings power associated with the company's biotechnology business model. The stock's 52-week price range spans from a low of $476.49 to a high of $821.11, providing context for the current trading position relative to its historical volatility over the past year. The beta of 0.40 indicates that the stock's price volatility is substantially lower than the broader market, suggesting that Regeneron's price movements are less sensitive to general market fluctuations compared to the average equity.
Growth & Income
The company's revenue growth rate is 2.5% year-over-year while earnings growth is -2.6% year-over-year, indicating that earnings are currently shrinking at a faster rate than revenue, which can be attributed to one-time costs, changes in tax provisions, or non-recurring expenses impacting the bottom line more sharply than top-line sales. As a dividend payer, Regeneron offers a dividend yield of 0.5% with a payout ratio of 8.5%, a low figure that suggests the dividend is highly sustainable given the company's strong cash flow and earnings position. The low payout ratio leaves ample room for the company to reinvest earnings into growth initiatives, research, and development rather than distributing the majority of profits to shareholders. Overall, the company presents a profile characterized by moderate revenue expansion, a contraction in reported earnings, and a conservative income strategy that prioritizes capital retention for long-term innovation over aggressive dividend growth.